Author: Gunter, Margaret J ; Simon, Steven R ; Chan, K Arnold ; Lafata, Jennifer Elston ; Chester, Elizabeth A ; Nelson, Winnie W ; Raebel, Marsha A ; Platt, Richard ; Andrade, Susan E ; Davis, Robert L ; Feldstein, Adrianne ; Carroll, Nikki M

OBJECTIVESTo describe the proportion of patients receiving drugs with a narrow therapeutic range who lacked serum drug concentration monitoring during a 1-year period of therapy and to identify patient characteristics associated with lack of monitoring.STUDY DESIGNRetrospective cohort.METHODSAmbulatory patients (n = 17,748) at 10 health maintenance organizations who were receiving ongoing continuous drug therapy with digoxin, carbamazepine, divalproex sodium, lithium carbonate, lithium citrate, phenobarbital sodium, phenytoin, phenytoin sodium, primidone, quinidine gluconate, quinidine sulfate, procainamide hydrochloride, theophylline, theophylline sodium glycinate, tacrolimus, or cyclosporine for at least 12 months between January 1, 1999, and June 30, 2001, were identified. Serum drug concentration monitoring was assessed from administrative data and from medical record data.RESULTSFifty percent or more of patients receiving digoxin, theophylline, procainamide, quinidine, or primidone were not monitored, and 25% to 50% of patients receiving divalproex, carbamazepine, phenobarbital, phenytoin, or tacrolimus were not monitored. Younger age was associated with lack of monitoring for patients prescribed digoxin (adjusted odds ratio, 1.86; 95% confidence interval, 1.39-2.48) and theophylline (adjusted odds ratio, 1.58; 95% confidence interval, 1.23-2.04), while older age was associated with lack of monitoring for patients prescribed carbamazepine (adjusted odds ratio, 0.59; 95% confidence interval, 0.44-0.80) and divalproex (adjusted odds ratio, 0.50; 95% confidence interval, 0.38-0.66). Patients with fewer outpatient visits were also less likely to be monitored (P < .001).CONCLUSIONSA substantial proportion of ambulatory patients receiving drugs with narrow intervals between doses resulting in beneficial and adverse effects did not have serum drug concentration monitoring during 1 year of use. Clinical implications of this finding need to be evaluated.

15 Dec 2005·The Journal of Chemical PhysicsQ2 · CHEMISTRY

Hydration number of glycine in aqueous solution: An experimental estimate

Q2 · CHEMISTRY

Article

Author: Parsons, Matthew T. ; Koga, Yoshikata

An experimental estimate of hydration number, NH, of glycine in aqueous solution is given by using the calorimetric methodology developed by us earlier, which is briefly reviewed. We found NH to be 7±0.6 for glycine presumably in the zwitter ion form, 10±1 for sodium glycinate, and 5±0.4 for glycine hydrochloride. Both glycine and sodium glycinate seem to work purely as a hydration center without altering the nature of the bulk H2O away from the hydration shell. Glycine hydrochloride, in addition to the role of hydration center, seems also to act as a typical hydrophilic species such as polyols, urea, or polyethylene glycols. Hence, the effect of the latter on H2O is of a long range, like other hydrophilic species.

01 Jan 2003·Biomedical ChromatographyQ4 · MEDICINE

Pharmacokinetics of a new sustained‐release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen

Q4 · MEDICINE

Article

Author: M. Qi ; L. Fang ; D. Zhong ; P. Wang

AbstractPharmacokinetics of a new sustained‐release formulation of theophylline sodium glycerinate in healthy subjects was studied. In this study, a new asymmetric dosage regimen was presented to achieve a better accordance with the chronotherapy of asthma. Each of 10 subjects was administered one tablet (equivalent to 0.1 g anhydrous theophylline) in the morning and four tablets in the evening for a consecutive 6 days and blood samples were collected at the predetermined time and analyzed by a validated HPLC method. This new regimen produced a steady and effective level of theophylline in plasma for the whole day, especially in the evening. A lower dose in the morning could reach the effective level (Cmin4.97 ± 1.60 µg/mL and Cmax10.68 ± 1.80 µg/mL over the a.m. dosing interval) and a higher dose in the evening did not result in toxic levels but led to a reasonable concentration range (Cmax9.72 ± 1.56 µg/mL over p.m. dosing interval), which could maintain a higher plasma theophylline concentration without the risk of serious adverse events and control asthmatic symptoms probably occurring during the night or early in the morning. The results suggested that the proposed asymmetric regimen was necessary, practicable and safe for twice daily sustained‐release tablets of theophylline sodium glycerinate and also provides the basis for the clinical dosage regimen of other theophylline formulated products. Copyright © 2003 John Wiley & Sons, Ltd.

100 Deals associated with Theophylline Sodium Glycinate

External Link

KEGG	Wiki	ATC	Drug Bank
D06104	-	R03DA04	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Asthma	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1995
Bronchitis	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1995
Pulmonary Edema	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1995

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis